226,600 Shares in CVS Health Corp (CVS) Purchased by Senzar Asset Management LLC

Senzar Asset Management LLC purchased a new position in shares of CVS Health Corp (NYSE:CVS) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 226,600 shares of the pharmacy operator’s stock, valued at approximately $18,233,000. CVS Health makes up about 4.5% of Senzar Asset Management LLC’s holdings, making the stock its 10th largest position.

Several other institutional investors have also bought and sold shares of CVS. Gemmer Asset Management LLC grew its position in shares of CVS Health by 15.3% in the 2nd quarter. Gemmer Asset Management LLC now owns 1,509 shares of the pharmacy operator’s stock valued at $121,000 after buying an additional 200 shares during the last quarter. TB Alternative Assets Ltd. bought a new stake in shares of CVS Health in the 2nd quarter valued at about $121,000. Captrust Financial Advisors bought a new stake in shares of CVS Health in the 2nd quarter valued at about $155,000. SRS Capital Advisors Inc. grew its position in shares of CVS Health by 48.2% in the 1st quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock valued at $177,000 after buying an additional 734 shares during the last quarter. Finally, Grace & White Inc. NY bought a new stake in shares of CVS Health in the 2nd quarter valued at about $199,000. 82.24% of the stock is owned by institutional investors.

A number of research analysts have recently issued reports on CVS shares. Citigroup dropped their price objective on CVS Health from $88.00 to $87.00 and set a “neutral” rating on the stock in a research note on Thursday, August 17th. Royal Bank Of Canada started coverage on CVS Health in a research note on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 price objective on the stock. Jefferies Group boosted their price objective on CVS Health from $82.00 to $86.00 and gave the company a “hold” rating in a research note on Friday, September 15th. Wolfe Research downgraded CVS Health from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $89.00 to $82.00 in a research note on Monday, August 14th. Finally, Loop Capital set a $73.00 price objective on CVS Health and gave the company a “hold” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have given a buy rating to the stock. CVS Health presently has a consensus rating of “Buy” and a consensus target price of $86.35.

In other news, EVP Thomas M. Moriarty sold 90,267 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.61, for a total value of $7,186,155.87. Following the completion of the sale, the executive vice president now directly owns 70,102 shares of the company’s stock, valued at $5,580,820.22. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Thomas M. Moriarty sold 20,547 shares of the stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $81.17, for a total value of $1,667,799.99. Following the completion of the sale, the executive vice president now directly owns 43,178 shares of the company’s stock, valued at $3,504,758.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 714,125 shares of company stock valued at $58,119,381. Company insiders own 0.61% of the company’s stock.

CVS Health Corp (CVS) traded up $0.37 during mid-day trading on Thursday, reaching $71.38. The company had a trading volume of 12,371,700 shares, compared to its average volume of 6,904,070. CVS Health Corp has a fifty-two week low of $66.45 and a fifty-two week high of $84.72. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. The firm has a market cap of $71,932.56, a P/E ratio of 12.44, a P/E/G ratio of 1.22 and a beta of 0.89.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The business had revenue of $46.18 billion for the quarter, compared to the consensus estimate of $46.17 billion. During the same period in the prior year, the business earned $1.64 EPS. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. equities analysts predict that CVS Health Corp will post 5.9 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2017/12/07/226600-shares-in-cvs-health-corp-cvs-purchased-by-senzar-asset-management-llc.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply